BR112014018918A8 - Terapia de combinação compreendendo hemifumarato de tenofovir alafenamida e cobicistato para uso no tratamento de infecções virais - Google Patents

Terapia de combinação compreendendo hemifumarato de tenofovir alafenamida e cobicistato para uso no tratamento de infecções virais

Info

Publication number
BR112014018918A8
BR112014018918A8 BR112014018918A BR112014018918A BR112014018918A8 BR 112014018918 A8 BR112014018918 A8 BR 112014018918A8 BR 112014018918 A BR112014018918 A BR 112014018918A BR 112014018918 A BR112014018918 A BR 112014018918A BR 112014018918 A8 BR112014018918 A8 BR 112014018918A8
Authority
BR
Brazil
Prior art keywords
cobicistat
tenofovir alafenamide
alafenamide hemifumarate
treatment
viral infections
Prior art date
Application number
BR112014018918A
Other languages
English (en)
Other versions
BR112014018918A2 (pt
Inventor
Ramanathan Srinivasan
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of BR112014018918A2 publication Critical patent/BR112014018918A2/pt
Publication of BR112014018918A8 publication Critical patent/BR112014018918A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

TERAPIA DE COMBINAÇÃO COMPREENDENDO HEMIFUMARATO DE TENOFOVIR ALAFENAMIDA E COBICISTATO PARA USO NO TRATAMENTO DE INFECÇÕES VIRAIS. A invenção refere-se ao uso da forma hemifumarato de {9-[(R)-2-[[(S)-[[(S)-1-(isopropoxicarbonil)etil]amino]fenoxifosfinil]metóxi]-propil]adenina} (hemifumarato de tenofovir alafenamida) em combinação com cobicistato que é revelado. Ainda, a combinação de hemifumarato de tenofovir alafenamida, cobicistato, emtricitabina e elvitegravir e a combinação de hemifumarato de tenofovir alafenamida, cobicistato, emtricitabina e darunavir são reveladas.
BR112014018918A 2012-02-03 2013-02-01 Terapia de combinação compreendendo hemifumarato de tenofovir alafenamida e cobicistato para uso no tratamento de infecções virais BR112014018918A8 (pt)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201261594894P 2012-02-03 2012-02-03
US201261618411P 2012-03-30 2012-03-30
US201261624676P 2012-04-16 2012-04-16
US201261692392P 2012-08-23 2012-08-23
US201261737493P 2012-12-14 2012-12-14
PCT/US2013/024438 WO2013116720A1 (en) 2012-02-03 2013-02-01 Combination therapy comprising tenofovir alafenamide hemifumarate and cobicistat for use in the treatment of viral infections

Publications (2)

Publication Number Publication Date
BR112014018918A2 BR112014018918A2 (pt) 2017-06-20
BR112014018918A8 true BR112014018918A8 (pt) 2017-07-11

Family

ID=47722563

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014018918A BR112014018918A8 (pt) 2012-02-03 2013-02-01 Terapia de combinação compreendendo hemifumarato de tenofovir alafenamida e cobicistato para uso no tratamento de infecções virais

Country Status (15)

Country Link
US (2) US20150105350A1 (pt)
EP (1) EP2809323A1 (pt)
JP (1) JP6059255B2 (pt)
KR (1) KR20140119177A (pt)
CN (1) CN104105484A (pt)
AU (3) AU2013204727A1 (pt)
BR (1) BR112014018918A8 (pt)
CA (1) CA2863662A1 (pt)
EA (1) EA026138B1 (pt)
HK (2) HK1202801A1 (pt)
IL (1) IL233874A0 (pt)
MD (1) MD20140091A2 (pt)
MX (1) MX2014009172A (pt)
NZ (1) NZ629896A (pt)
WO (2) WO2013116730A1 (pt)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG183059A1 (en) 2007-02-23 2012-08-30 Gilead Sciences Inc Modulators of pharmacokinetic properties of therapeutics
ES2623794T3 (es) 2008-12-09 2017-07-12 Gilead Sciences, Inc. Intermedios para la preparación de moduladores de receptores tipo toll
RS55353B2 (sr) * 2011-08-16 2023-11-30 Gilead Sciences Inc Tenofovir alafenamid hemifumarat
CN103665043B (zh) 2012-08-30 2017-11-10 江苏豪森药业集团有限公司 一种替诺福韦前药及其在医药上的应用
MX2016002560A (es) * 2013-08-29 2016-10-26 Teva Pharma Forma de dosificacion unitaria que comprende emtricitabina, tenofovir, darunavir y ritonavir y un comprimido monolitico que comprende darunavir y ritonavir.
WO2015079455A2 (en) * 2013-11-27 2015-06-04 Laurus Labs Private Limited A recycling process for preparing tenofovir alafenamide diastereomers
US9463194B2 (en) 2014-02-05 2016-10-11 Gilead Sciences, Inc. Methods of treating patients co-infected with HIV and tuberculosis
EP3129009A1 (en) * 2014-04-08 2017-02-15 Teva Pharmaceutical Industries Ltd Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir
WO2015161785A1 (zh) * 2014-04-21 2015-10-29 四川海思科制药有限公司 氨基磷酸酯类衍生物制备方法及其中间体和中间体的制备方法
US11311519B2 (en) 2014-05-01 2022-04-26 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
US10076512B2 (en) 2014-05-01 2018-09-18 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
PL3166607T3 (pl) * 2014-07-11 2023-02-20 Gilead Sciences, Inc. Modulatory receptorów toll-podobnych do leczenia hiv
CN106715431A (zh) 2014-09-16 2017-05-24 吉利德科学公司 Toll样受体调节剂的固体形式
CN105237571B (zh) * 2014-11-28 2018-03-09 成都苑东生物制药股份有限公司 9‑[(r)‑2‑[[(s)‑[[(s)‑1‑(异丙氧基羰基)乙基]氨基]苯氧基氧膦基]甲氧基]丙基]腺嘌呤的盐
WO2016090107A2 (en) * 2014-12-04 2016-06-09 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
KR20170123308A (ko) 2014-12-26 2017-11-07 에모리 유니버시티 Ｎ4-하이드록시시티딘, 이와 관련된 유도체 및 이의 항 바이러스적 용도
US20170348334A1 (en) * 2015-01-03 2017-12-07 Mylan Laboratories Limited Processes for the preparation of amorphous tenofovir alafenamide hemifumarate and a premix thereof
CN107530338B (zh) 2015-04-21 2020-12-01 艾格尔峰生物制药有限公司 包含洛那法尼和利托那韦的药物组合物
CN104817593B (zh) * 2015-04-27 2016-11-16 广州同隽医药科技有限公司 半富马酸替诺福韦艾拉酚胺关键中间体的合成工艺
CA2921336A1 (en) * 2015-06-30 2016-12-30 Gilead Sciences, Inc. Pharmaceutical formulations
PT3607939T (pt) * 2015-06-30 2022-09-12 Gilead Sciences Inc Formulações farmacêuticas compreendendo tenofovir e emtricitabina
WO2017023694A1 (en) 2015-08-03 2017-02-09 Pop Test Oncology Llc Pharmaceutical compositions and methods
CN105153231A (zh) * 2015-08-28 2015-12-16 浙江车头制药股份有限公司 一种一苯基pmpa的制备方法
CN113546052A (zh) 2015-11-09 2021-10-26 吉利德科学公司 治疗人免疫缺陷病毒的治疗组合物
US20170232020A1 (en) * 2016-02-12 2017-08-17 Cipla Limited Pharmaceutical compositions
CN107179355B (zh) * 2016-03-11 2021-08-10 广东东阳光药业有限公司 一种分离检测替诺福韦艾拉酚胺及其有关物质的方法
US10449208B2 (en) * 2016-08-25 2019-10-22 Merck Sharp & Dohme Corp. Antiviral prodrugs of tenofovir
CN108070003A (zh) * 2016-12-02 2018-05-25 上海博志研新药物技术有限公司 替诺福韦艾拉酚胺半反丁烯二酸盐晶型及制备方法和应用
RU2659388C1 (ru) 2017-02-28 2018-07-02 Васильевич Иващенко Александр Нуклеотиды, включающие N-[(S)-1-циклобутоксикарбонил]фосфорамидатный фрагмент, их аналоги и их применение
US20190374557A1 (en) * 2017-02-28 2019-12-12 Alexandre Vasilievich Ivachtchenko Cyclobutyl (S)-2-[[[(R)-2-(6-aminopurin-9-yl)-1-methyl-ethoxy]methyl-phenoxy-phosphoryl]amino]-propanoates, and production process and application thereof
CN106928277A (zh) * 2017-03-16 2017-07-07 江苏诚信药业有限公司 一种替诺福韦艾拉酚胺合成的工艺方法
AU2018239257B2 (en) 2017-03-20 2023-09-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services HIV post-exposure prophylaxis
AU2018255954B2 (en) * 2017-04-18 2024-04-04 Cipla Limited Combination therapy for use in treating retroviral infections
RU2659693C1 (ru) * 2017-06-30 2018-07-03 Общество с ограниченной ответственностью "Изварино Фарма" Фармацевтическая композиция, обладающая активностью против ВИЧ-инфекции
EP3700573A1 (en) * 2017-10-24 2020-09-02 Gilead Sciences, Inc. Methods of treating patients co-infected with a virus and tuberculosis
BR122022008466B1 (pt) 2017-12-07 2023-12-05 Emory University Uso de um composto
CN110305163A (zh) * 2018-03-27 2019-10-08 北京济美堂医药研究有限公司 替诺福韦艾拉酚胺半富马酸盐的制备方法
CN108484672A (zh) * 2018-05-23 2018-09-04 中国药科大学制药有限公司 磷丙替诺福韦的手性拆分方法
CN109081853A (zh) * 2018-09-03 2018-12-25 南京正大天晴制药有限公司 一种磷丙替诺福韦有关物质的制备方法
US20220265689A1 (en) 2019-07-19 2022-08-25 THE UNITED STATES OF AMERICA , as represented by the Secretary, Department of Health and Human Hiv pre-exposure prophylaxis
CN111606949A (zh) * 2020-03-13 2020-09-01 浙江车头制药股份有限公司 一种磷丙替诺福韦杂质的制备方法
CN111303209A (zh) * 2020-03-21 2020-06-19 石家庄龙泽制药股份有限公司 一种丙酚替诺福韦降解杂质的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB453061A (en) 1935-03-23 1936-09-04 Charles Howard Twigg Improvements in and relating to gas heated geysers and water heaters
US5922695A (en) 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
KR100767432B1 (ko) 2000-07-21 2007-10-17 길리애드 사이언시즈, 인코포레이티드 포스포네이트 뉴클레오티드 유사체의 전구 약물과 그것의 선택 및 제조 방법
DE10153078A1 (de) 2001-10-30 2003-05-22 Degussa Verwendung von Granulaten auf Basis von pyrogen hergestelltem Siliciumdioxid in pharmazeutischen Zusammensetzungen
DE602004014470D1 (de) 2003-01-14 2008-07-31 Gilead Sciences Inc Zusammensetzungen und verfahren zur antiviralen kombinationstherapie
SG183059A1 (en) * 2007-02-23 2012-08-30 Gilead Sciences Inc Modulators of pharmacokinetic properties of therapeutics
US8354421B2 (en) 2007-06-29 2013-01-15 Korea Research Insitute Of Chemical Technology HIV reverse transcriptase inhibitors
MX2011008289A (es) * 2009-02-06 2011-09-15 Gilead Sciences Inc Tabletas para terapia combinada.
RS55353B2 (sr) * 2011-08-16 2023-11-30 Gilead Sciences Inc Tenofovir alafenamid hemifumarat

Also Published As

Publication number Publication date
AU2013204731A1 (en) 2013-08-22
EA026138B1 (ru) 2017-03-31
KR20140119177A (ko) 2014-10-08
MX2014009172A (es) 2014-08-27
IL233874A0 (en) 2014-09-30
WO2013116730A1 (en) 2013-08-08
NZ629896A (en) 2016-03-31
BR112014018918A2 (pt) 2017-06-20
HK1202801A1 (en) 2015-10-09
MD20140091A2 (ro) 2015-01-31
US20170056423A1 (en) 2017-03-02
AU2013204731C1 (en) 2017-08-31
AU2013204731B2 (en) 2016-03-03
HK1204914A1 (en) 2015-12-11
CN104105484A (zh) 2014-10-15
JP6059255B2 (ja) 2017-01-11
AU2013204727A1 (en) 2013-08-22
JP2015505565A (ja) 2015-02-23
EP2809323A1 (en) 2014-12-10
US20150105350A1 (en) 2015-04-16
EA201491287A1 (ru) 2015-04-30
AU2016203666A1 (en) 2016-06-23
CA2863662A1 (en) 2013-08-08
WO2013116720A1 (en) 2013-08-08

Similar Documents

Publication Publication Date Title
BR112014018918A8 (pt) Terapia de combinação compreendendo hemifumarato de tenofovir alafenamida e cobicistato para uso no tratamento de infecções virais
MD4508B1 (ro) Hemifumarat de tenofovir alafenamidă şi utilizările sale medicale
PH12015500758A1 (en) Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases
PH12015502780A1 (en) Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases
PH12015500073A1 (en) Macrocyclic purines for the treatment of viral infections
PH12015500274B1 (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
MY169159A (en) Piperidino-pyrimidine derivatives for the treatment of viral infections
PH12015500713A1 (en) Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases
EA201490947A1 (ru) Производные пурина для лечения вирусных инфекций
PT2898885T (pt) Derivados de pirrolopirimidina para utilização no tratamento de infeções virais
CL2015001342A1 (es) Compuestos derivados de pirrolo[3,2-d]pirimidina; composicion farmaceutica y de vacuna que los comprende y el uso en el tratamiento de enfermedades alergicas y otras enfermedades inflamatorias, infecciosas y cancer.
BR112013024809A2 (pt) tratamento para infecção com vírus de hepatite b sozinho ou em combinação com vírus de hepatite delta e doenças do fígado associadas
BR112014026158A2 (pt) métodos e composições para o tratamento de infecções virais
UA81083U (ru) Способ лечения больных острыми респираторными вирусными инфекциями
UA66165U (ru) Применение витаминной композиции, которая содержит витамины С и К3, в качестве средства для лечения вирусных инфекций

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]